₹977.20
−2.42%NSE close, 16 Nov 2026
+12.34%
Windlas Biotech is a small cap company, listed on NSE under the symbol WINDLAS. At ₹977.20 a share, the market values the whole company at ₹2,017 crore.
In FY26, it reported sales of ₹904 crore and a net profit of ₹66 crore, an operating margin of 11.6%. Over the last three years, sales grew 20.8% a year and net profit grew 16.0% a year.
The market values the company at 30.2 times its profit over the last twelve months and 3.54 times its book value; its return on equity is 11.7% and its borrowings are 0.08 times its equity.
Promoters hold 63.31% of the shares. Foreign institutions hold 2.08%, and domestic institutions, mutual funds among them, 7.24%.
Over the past year the share price has risen 5.9%, and it is 17.3% below its 52-week high.
₹ crore. Consolidated figures where the company filed them, standalone otherwise (marked S).
Transcript
Link of Recording
Windlas Biotech Limited Reports its H1 & Q2 FY27 Financial Results
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 S |
|---|
| Sep 2026 S |
|---|
| Sales | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 239 | 248 | 264 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 | 221 | 235 |
| Operating profit | 20.3 | 22.0 | 20.9 | 23.1 | 24.6 | 25.6 | 26.5 | 28.6 | 24.4 | 25.3 | 26.7 | 29.4 |
| Operating margin | 12.5% | 12.8% | 11.9% | 12.3% | 12.6% | 12.6% | 12.6% | 12.8% | 10.5% | 10.6% | 10.8% | 11.1% |
| Other income | 3.2 | 4.4 | 4.1 | 4.8 | 4.1 | 4.9 | 5.2 | 3.7 | 4.6 | 4.4 | 5.1 | 3.9 |
| Interest | 0.3 | 0.3 | 0.5 | 1.1 | 1.5 | 1.3 | 1.1 | 1.0 | 1.3 | 1.5 | 1.7 | 2.3 |
| Depreciation | 3.4 | 3.5 | 6.2 | 6.5 | 6.9 | 8.3 | 7.5 | 7.6 | 7.7 | 8.0 | 7.2 | 7.6 |
| Profit before tax | 19.8 | 22.6 | 18.3 | 20.3 | 20.3 | 20.8 | 23.3 | 23.6 | 20.0 | 20.2 | 22.9 | 23.3 |
| Tax | 4.7 | 5.6 | 4.8 | 4.6 | 4.8 | 4.5 | 5.6 | 5.8 | 5.0 | 4.2 | 5.3 | 5.3 |
| Net profit | 15.1 | 17.0 | 13.5 | 15.7 | 15.6 | 16.3 | 17.7 | 17.8 | 15.0 | 16.0 | 17.7 | 18.1 |
| EPS (₹) | 7.26 | 8.17 | 6.47 | 7.49 | 7.45 | 7.77 | 8.43 | 8.48 | 7.12 | 7.58 | 8.46 | 8.75 |
₹ crore, financial years to March.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 466 | 513 | 631 | 760 | 904 |
| Expenses | 414 | 453 | 553 | 666 | 799 |
| Operating profit | 52.4 | 60.2 | 78.2 | 94.1 | 105 |
| Operating margin | 11.3% | 11.7% | 12.4% | 12.4% | 11.6% |
| Other income | 6.7 | 10.0 | 13.5 | 18.0 | 17.8 |
| Interest | 1.4 | 0.8 | 1.1 | 4.4 | 4.8 |
| Depreciation | 12.2 | 12.4 | 13.5 | 28.0 | 30.7 |
| Profit before tax | 45.6 | 57.0 | 77.1 | 79.8 | 87.0 |
| Tax | 7.5 | 14.4 | 18.9 | 18.8 | 20.5 |
| Net profit | 37.9 | 42.6 | 58.2 | 61.0 | 66.5 |
| EPS (₹) | 18.80 | 19.69 | 27.97 | 29.19 | 31.60 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 9.1 | 68.2 | 105 | 53.5 |
| From investing | −155 | −74.1 | −91.8 | −2.8 |
| From financing | 130 | 1.0 | −13.0 | −50.2 |
| Spent on fixed assets | −14.8 | −52.2 | −67.7 | 0 |
| Free cash flow | −5.7 | 16.0 | 37.3 | 53.5 |
Margins, returns, debt, tax and cash.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net margin | 8.1% | 8.3% | 9.2% | 8.0% | 7.4% |
| Operating margin | 11.3% | 11.7% | 12.4% | 12.4% | 11.6% |
| Return on equity | – | 10.6% | 12.9% | 12.1% | 11.4% |
| Return on capital employed | – | 14.4% | 17.4% | 15.8% | 15.0% |
| Return on assets | – | 8.1% | 9.3% | 8.0% | 7.3% |
| Debt to equity | – | 0.00 | 0.00 | 0.05 | 0.05 |
| Interest coverage | 33.10 | 72.30 | 70.50 | 19.20 | 19.00 |
| Debt to assets | – | 0.00 | 0.00 | 0.04 | 0.03 |
| Current ratio | – | 2.92 | 2.51 | 2.11 | 1.95 |
| Quick ratio | – | 2.30 | 2.15 | 1.78 | 1.76 |
| Cash ratio | – | 0.03 | 0.03 | 0.00 | 0.00 |
| Asset turnover | – | 0.97 | 1.01 | 1.00 | 1.00 |
| Fixed asset turnover | – | 5.00 | 3.72 | 3.89 | 4.83 |
| Inventory turnover | – | – | 6.40 | 5.80 | 9.00 |
| Receivables turnover | – | 4.40 | 4.60 | 4.60 | 4.00 |
| Gross margin | – | – | 37.2% | 37.9% | 38.4% |
| Cash from operations to profit | 24.0% | – | – | 112.0% | 158.0% |
| Effective tax rate | 16.4% | 25.3% | 24.5% | 23.5% | 23.6% |
Mr. Ashok Kumar Windlass appointed as Founder President (Senior Management Personnel) effective from November 6, 2026
Resignation of Mr. Ashok Kumar Windlass as Executive Director of the company w.e.f. November 05, 2026.
The financial results for the period ended September 30, 2026.
Cyber Security Incident
Schedule of meet
Schedule of meet
Press release on "Windlas Biotech Limited Reports its Q1 FY27 Financial Results